Evidence map›Paper›PMID 40950828›Full record

ArticleThe Pan African medical journal2025

Seroprevalence and persistence of humoral immunity in response to SARS-CoV-2 vaccination and mild infection in Morocco: a cross-sectional study.

Nouhaila Najimi, Chaimae Kadi, Zainab Gaouzi, Nadia Dakka, Rabii Ameziane El Hassani, Fouad Seghrouchni, Youssef Bakri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nouhaila NajimiLaboratory of Human Pathologies and Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Chaimae KadiMohammed VI University of Sciences and Health, Casablanca, Morocco.
Zainab GaouziMohammed VI University of Sciences and Health, Casablanca, Morocco.
Nadia DakkaLaboratory of Human Pathologies and Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Rabii Ameziane El HassaniLaboratory of Human Pathologies and Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Fouad SeghrouchniInstitut Supérieur des Professions Infirmières et Techniques de Santé, Rabat, Maroc.
Youssef BakriLaboratory of Human Pathologies and Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: assessing the seroprevalence and persistence of humoral immunity through population-based serological surveys is crucial for predicting reinfection risk and optimizing vaccination strategies. In Morocco, a mass vaccination campaign against SARS-CoV-2 has been launched to achieve herd immunity and reduce virus transmission. This study evaluated the humoral immune response to the BBIBP-CorV and ChAdOx1 nCoV-19 vaccines in healthy donors with varying doses and infection histories. Methods: IgG levels were measured via Vircell COVID-19 ELISA, and NAb levels were assessed via the GenScript Surrogate Virus Neutralization Test (sVNT). The study included individuals with different vaccination doses and prior infection histories. Results: the third vaccine dose produced the highest IgG titers, while nonvaccinated individuals and those receiving two doses had lower levels. Prior SARS-CoV-2 infection led to increased antibody levels, suggesting that hybrid immunity offers prolonged protection. The highest NAb titers were observed in individuals receiving three doses, with 96% of previously noninfected individuals being positive for NAb. Risk factor analysis indicated that prior infection (OR = 8.64, 95% CI: 2.52-29.6, p < 0.001) and three doses (OR = 22.1, 95% CI: 2.74-178, p < 0.001) increased immunity. Conclusion: hybrid immunity, involving prior infection and full vaccination, offers enhanced and longer-lasting protection. These results support the need for targeted vaccination strategies to optimize immunity and reduce the risk of adverse outcomes, especially in high-risk populations.

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesImmunity, HumoralAdolescentAdultAntibodies, NeutralizingChAdOx1 nCoV-19Cross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansImmunity, HerdImmunoglobulin GMaleMass VaccinationAntibodies, NeutralizingAntibodies, ViralChAdOx1 nCoV-19COVID-19 VaccinesImmunoglobulin GBBIBP-CorV vaccineChAdOx1 nCoV-19 vaccinehumoral immunityhybrid immunityMorocconeutralizing antibodiesrisk factorsSARS-CoV-2 infectionSeroprevalence

Identifiers

PMID40950828
PMCPMC12433016

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.